Pfizer – PARP-inhibitor Combination Treatments in Prostate Cancer – RFP
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire within unit
Memorial Deadline: Monday 17th, April 2023
External Deadline: Monday 24th, April 2023
Description
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP. For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program. |
Date RFP Issued: March 30, 2023
Geographic Scope: Global Clinical Area: Oncology – Genitourinary – Prostate Link to full RFP: PARP-inhibitor Combination Treatments in Prostate Cancer Application Due Date: April 24, 2023 Specific Area of Interest: Projects that will be considered for Pfizer support will focus on:
|
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Dewayne Brumlow, Grant Officer (dewayne.brumlow@pfizer.com).